Background
Lung cancer remains the leading cause of cancer-related mortality (www.who.int/cancer/en) causing 1.59 million death worldwide per year. Lungs are the most common sites of metastatic disease and tumour relapse after the treatment of the primary mass. Since lung tumours are largely disseminated in the pulmonary parenchyma, their excision is often difficult and not resolving causing a median survival time of less than one year. For these reasons it is important to develop less invasive treatments able to discriminate between healthy and pathological tissues at cellular level. Boron neutron capture therapy (BNCT) is an experimental binary radiation therapy currently under intense scrutiny for the treatment of cancer, especially head and neck recurrent tumours . This fact makes BNCT a promising option for the treatment of disseminated tumours, such as pulmonary metastases that cannot be treated by methods requiring a precise localization of the pathological tissue, like surgery, conventional photon-therapies or heavy ion-therapy. The selective delivery to tumour cells is crucial to increase the amount of internalized boron maintaining, at the same time, a low concentration in surrounding healthy tissues and in blood to minimize damage. Currently, two BNCT drugs are available for clinical investigation namely: i)Lpara-boronophenylalanine (BPA), structurally related to the amino acid phenylalanine, that has been used in clinical trials to treat glioblastoma, head and neck recurrent cancer and melanoma 7 and ii) sodium mercaptoundecahydro-closo-dodecaborate (BSH) that has been investigated for the treatment of malignant glioma 8 . . Carboranes are icosahedral cages containing 10 boron atoms and they have been used to design boron delivery vehicles due to their high boron content, chemical versatility and in vivo stability [10] [11] . Carborane based agents may be functionalized with small targeting moieties including amino acids, vitamins, carbohydrates, porphyrinates, ect. 12 to achieve tumour selectivity. A different strategic concept for selectively introducing boron into tumour cells is based on the covalent binding of multiple carborane cages to monoclonal antibodies 13 or their incorporation into large entities such as, liposomes [14] [15] , low-density lipoproteins [16] [17] [18] (LDL) or other nanoparticles.
Despite the current availability of many carborane derivatives that have given significant results in preclinical studies, none has been translated to the clinical setting. A crucial issue to reach this goal is the assessment of the boron amount in the tumour tissue. This is important in order to proceed with the neutron irradiation, because successful results can only be expected if the boron concentration threshold has been reached, and if a proper dose prescription is performed according to the therapeutic goal and the sparing of the normal tissue. Currently, boron concentrations in tumour are estimated in clinical trials using empirical data models that depend on tumour-to-blood, tumour-tobrain and brain-to-blood boron concentration ratios. One of the problems is that the uptake and distribution of boron varies among patients and that large uncertainties exist in the tumour-to-blood boron concentration ratio 19 . Only proper Neutron Capture Therapy (NCT) agent design, based on an improved knowledge of how molecules enter healthy and cancer cells, could allow the optimal intracellular concentration, needed to make NCT an effective therapy to cure cancer, to be reached. . LDLs have been identified as good carriers of boron cluster since the expression of
LDLRs is up-regulated in many tumours 25, 26 . Furthermore these nanoparticles can carry a high number of boron atoms without losing the specific internalization pathway. For NCT treatment, the AT101 ligand was chelated using GdCl3 enriched in the isotope 157 to exploit its high thermal neutron cross-sections of around 255000 barns 27 . This cross-section provides a roughly 65-fold improvement upon the one of implies that during the lung irradiation, the whole body of the animal is indirectly exposed to the neutron field. In order to protect the healthy organs of the animal body a shield made of 95% 6 Lienriched Li2CO3 powder was used as neutron absorber, due to the absence of secondary gamma radiation after 6 Li neutron capture Evaluation of the AT101/LDL particle uptake "in vivo" in pulmonary metastasis.
In order to generate the lung metastasis mice model, 50000 TUBO cells have been injected Figure 3C reports the mean SI enhancement (%) at the different time intervals. As expected, high % SI enhancement are observed in the tumor region and in the liver due to the high LDLRs expression on both tumor cells and normal hepatocytes. On this basis, the liver has to be protected with a neutron shield during BNCT treatment.
The boron concentrations calculated at 3, 6 and 24h post-injection, using the method reported above, in the tumour, muscle (surrounding lungs), and liver are reported in Table 1 . The intra-tumour boron concentration was significantly above the established threshold of 20/30 ppm, which is suitable for efficient BNCT treatment. The ratio of the concentration of boron atoms derives from the comparison between the concentrations in the tumour and surrounding muscle. On the basis of these results 6h POST i.v. has been selected as the best time to perform BNCT. In fact, at this time, the high boron concentration in tumour (48 ppm) is combined with a high tumour/muscle boron ratio that is fundamental to avoid healthy tissues damage.
BNCT treatment of TUBO cells "in vitro".
For the BNCT studies the AT101 ligand has been chelated to Gd 3+ enriched in the isotope 157. Seven 
Irradiation set-up and radiation dose calculations.
Mice neutron irradiation was carried out using the same irradiation facility used for cells. To limit the neutrons dose absorbed by the liver and spleen, as AT101/LDL accumulate in these organs and to limit the neutron-induced radioactivity in the whole animal, neutron-absorbing shields made of 95% Table 2 and 3) .
To carry out a safe treatment, preliminary irradiations of wild type BALB/c mice (n=15) were performed using the described shielding without the administration of the boron containing compound. The irradiation time was increased from 10 up to 20 minutes, while the reactor power was kept at 250 kW. From these results (reported as supplementary materials in Figure S3 ), the time for the NCT irradiation was fixed to 15 minutes, taking into account the toxicity just described and the presence, during a real NCT, of the enhancement capture agents in the tissues. To assess the safety of this treatment plan, the doses were compared to a tolerance limit of about 7 Gy delivered in a total body X-or γ-ray irradiation of the mouse 36 . The dose contribution due to the 92.3% enrichment in 157 Gd was calculated as well. As anticipate, the biological effect was mainly expected from the Auger electrons which transport a very little fraction of the total energy emitted by 157 Gd capture reaction. As consequence, the contribution of this radiation in term of absorbed dose is pretty low. The MCNP simulations reported an enhancement of the total doses showed in Table 2 of about 5-6% in the lung metastases, while the same increment can be as high as around 10% in healthy tissues, depending on Gd concentration and organ position and shielding.
BNCT treatment of pulmonary metastasis.
BALB/c mice (n=40) received an i.v. injection of 50000 TUBO cells 3 weeks before BNCT treatment.
This led to the formation of several pulmonary metastasis that have been visualized by MRI using a T2-weighted RARE sequence. The number of metastasis varied markedly from mouse to mouse (from 5 to 20). The intratumour boron concentration has been determined by MRI 3h after the AT101/LDL administration and was of 43±10 ppm whereas 16±5 boron ppm have been found in the surrounding healthy muscle. Two groups of animals (n=15 for each group) underwent the irradiation treatment.
The first group received AT101/LDL at a Gd dose of 0.1 mmol/Kg corresponding to a boron dose of 10mg/Kg, 6h before neutron exposure. The second group (irradiated control group) received the same volume of PBS to assess the effect of neutron irradiation in the absence of AT101/LDL. A third group of non-irradiated mice (n=10) was used as a reference to assess tumour growth in the absence of any treatment and irradiation. Tumour size has been monitored by MRI using a T2-weighted RARE sequence. (Figure 5A-D) No growth of the tumour size was detected for irradiated and treated animals in the first 25 days after BNCT ( Figure 5E ). Only at longer times the tumour lesions slowly restarted their growth.
BNCT treatment of EML4-ALK transgenic mice.
EML4-ALK transgenic mice received the same treatment described above. At the day of irradiation, the tumour volumes of 6 weeks old EML4-ALK mice were between 0.5-15 mm 3 ( Figure 6A ). Boron concentrations were calculated 3h before BCNT treatment by MRI measuring the SI enhancement in the tumour regions in the T1 weighted images before and after the AT101/LDL administration and they were of 52±12 and 16±5 ppm in the tumour and surrounding muscle, respectively. On this basis it is possible to conclude that also in this model the intratumour amount of boron was enough to expect a significant regression of the tumour mass upon the neutron exposure. A limited toxic effect on the surrounding muscle is expected thanks to the three times lower boron concentration detected in these healthy tissues. Two groups of mice have been considered in this study. The first group (n=5) received AT101/LDL in a Gd dose of 0.1 mmol/Kg, 6h before neutron exposure. The second group (irradiated control group; n=5) received the same volume of PBS in order to assess the effect of neutron irradiation in the absence of AT101/LDL. Figure 6B shows that the tumour growth of mice irradiated after boron treatment was negligible for the first 30 days.
Discussion.
The proposed procedure, based on the destruction of the tumour bulk by BNCT using a boron/Gd dual nanosized delivery agent, opens a promising therapeutic opportunity for lung cancer treatments in particular in the presence of disseminated tumours. This approach has been tested on mammary metastases (obtained by injecting i.v. mammary carcinoma TUBO cells) and ALK-EML4 transgenic mouse models of lung carcinogenesis, that develop highly aggressive tumours with modality similar to that of human cancer. In this contest, the possibility to measure boron concentration indirectly by MRI exploiting the presence of the conjugated Gd CA, was fundamental to proceed with the best treatment duration, at the most advantageous time after boron administration and with a proper neutron fluence. In fact, successful results can only be expected if a sufficient dose is delivered to tumour while the dose absorbed to normal tissues is kept under the tolerance dose. In order to achieve this result, a combination of three factors is necessary: a suitable boron concentration in the tumour, a high tumour to normal tissue ratio and a sufficient neutron flux to irradiate animals in acceptable times. The observed tumour re-growth observed on both mice models about 25-30 days after the treatment may be accounted in terms of two possible explanations: i) it might be associated to the presence in the tumour mass of quiescent cells, for which a greater capacity to recover from radiation and chemotherapeutic agent-induced damage has been demonstrated 37, 38 . In addition, the higher resistance observed for these cells to targeted therapies could be the consequence of a lower expression of target receptors with respect to highly proliferating cells; ii) the neutron dose delivered to the lung tumour is not sufficient to kill all the cells. This may be due to the fact that the shielding set-up is a compromise between the need to protect the animal and the therapeutic effect gained by neutron irradiation. Actually, due to the proximity of lungs and liver, organs where AT101/LDL accumulates, it is difficult to design and locate the Lithium carbonate shield in a way that the healthy tissue is preserved while leaving the tumour exposed to neutron irradiation. 
